Referencia número: HY-N2959

Brevilin A

5 Cited Publications

Revisión del cliente

Based on 5 publication(s) in Google Scholar

Brevilin A is an orally active STAT3/JAK inhibitor (STAT3 IC₅₀=?10.6 μM). Brevilin A shows anti-tumor activity, anti-proliferative activity to cancer cells, and can induce apoptosis and autophagy.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza: 99.86%
No. CAS: 16503-32-5
Fòrmula: C₂₀H₂₆O₅
Peso molecular:346.42

Almacenamiento:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Brevilin A Chemical Structure

No. CAS: 16503-32-5

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Solvente y solubilidad
- In Vitro
- In Vivo
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target^[1]

STAT3

10.6 μM (IC₅₀)

Ver todos los productos específicos de isoformas JAK :

Ver todos los productos específicos de isoformas STAT :

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	IC₅₀	>10 μM Compound: 17	Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HCT-116 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33533247]
HeLa	IC₅₀	9.2 μM Compound: 17	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33533247]
HepG2	IC₅₀	>10 μM Compound: 17	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 33533247]

In Vitro

Brevilin A (1-20 μM; 24 h) inhibits STAT3 signaling in a dose dependent manner^[1].
Brevilin A (0-50 μM; 24-72 h) inhibits the proliferation of NPC cells^[2].
Brevilin A (10 μM; 24 and 48 h) induces DU145 and MDA-MB-468 apoptosis after 24 h treatment^[1].
Brevilin A (12.5 and 25 μM; 24 h) blocks STAT3 tyrosine 705 phosphorylation in A549R cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

A549R cells
Concentration:

1-20 µM
Incubation Time:

24 hours
Result:

Exhibited STAT3 signaling inhibition in a dose dependent manner with IC₅₀ value of 10.6 µM.

Cell Proliferation Assay^[2]

Cell Line:

CNE-2 cells
Concentration:

0-50 μM
Incubation Time:

24, 48, and 72 hours
Result:

Showed IC₅₀ values in CNE-2 cells with treatment times of 24, 48, and 72 h of 7.93, 2.60, and 22.26 µM, respectively.

Apoptosis Analysis^[1]

Cell Line:

DU145 and MDA-MB-468 cells
Concentration:

10 µM
Incubation Time:

24 and 48 hours
Result:

Decreased c-Myc and CyclinD1 after 24 h and 48 h treatment, increased cleaved PARP after 24 h treatment.

Western Blot Analysis^[1]

Cell Line:

A549R cells
Concentration:

12.5 and 25 µM
Incubation Time:

24 hours
Result:

Inhibits STAT3 phosphorylation in A549R cells.

In Vivo

Brevilin A (oral gavage; 10 and 20 mg/kg; once daily; 16 d) inhibits CNE-2 xenograft tumor growth, and inhibits PI3K/AKT and STAT3 signaling in vivo^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male BALB/c nude mice injected with CNE-2 cells^[2]
Dosage:

10 and 20 mg/kg
Administration:

Oral gavage; 10 and 20 mg/kg; once daily; 16 days
Result:

Decreased average tumor volumes and weights treated with 20 mg/kg by 36.3% and 46.0%, respectively, compared to vehicle control.
Inhibited the protein expression of p-AKT and p-STAT3 at both low and high doses.

Chemical Information

No. CAS 16503-32-5
Appearance Solid
Peso molecular 346.42
Fòrmula C₂₀H₂₆O₅
Color White to off-white
SMILES

C/C=C(C)\C(O[C@H]1[C@@]([C@@H]2C)([H])[C@@](OC2=O)([H])C[C@@H](C)[C@@]3([H])[C@]1(C(C=C3)=O)C)=O
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
Envío

Room temperature in continental US; may vary elsewhere.

Almacenamiento

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All Cell Proliferation/Viability AssayFlow CytometryCell Migration/Invasion AssayWBHistological Imaging/Staining

Sort by:

Journal Impact Factor

Phytomedicine

Brevilin A suppresses lipid metabolism reprogramming in colorectal adenoma-to-adenocarcinoma sequence via the NR1D1/APOH signaling axis. [Abstract]

2025 Oct 17:148:157386. PMID: 41110356
Cell Cycle

Entero-toxigenic Bacteroides fragilis contributes to intestinal barrier injury and colorectal cancer progression by mediating the BFT/STAT3/ZEB2 pathway. [Abstract]

2024 Jan;23(1):70-82. PMID: 38273425

Brevilin A purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2024 Jan;23(1):70-82. [Abstract]

Effect of Brevilin A a treatment and ZEB2-interfering lentivirus on SW480 cell viability using the CCK-8 assay.

Brevilin A purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2024 Jan;23(1):70-82. [Abstract]

Flow cytometry was performed to analyze the percentage of early and late apoptosis treated with Brevilin A.

Brevilin A purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2024 Jan;23(1):70-82. [Abstract]

Effect of Brevilin A and LV-ZEB2 on SW480 cell migration was analyzed by the wound healing assay.

Brevilin A purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2024 Jan;23(1):70-82. [Abstract]

Representative gel blot images of p-STAT3, STAT3, and ZEB2 treated with Brevilin A.

Brevilin A purchased from MedChemExpress. Usage Cited in: Cell Cycle. 2024 Jan;23(1):70-82. [Abstract]

HE staining was performed to observe the pathological changes of colonic tissue treated with Brevilin A (10 mg/kg, i.p.).
Mol Biotechnol

Brevilin A Inhibits Prostate Cancer Progression by Decreasing PAX5-Activated SOX4. [Abstract]

2024 May 14. PMID: 38744788
Ann Med Surg (Lond)

Brevilin A ameliorates sepsis-induced cardiomyopathy through inhibiting NLRP3 inflammation. [Abstract]

2023 Oct 17;85(12):5952-5962. PMID: 38098561
Research Square Preprint

2024 Mar 6.

Solvente y solubilidad

In Vitro:

DMSO : 100 mg/mL (288.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8867 mL

14.4333 mL

28.8667 mL

5 mM

0.5773 mL

2.8867 mL

5.7733 mL

10 mM

0.2887 mL

1.4433 mL

2.8867 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 10 mg/mL (28.87 mM); Clear solution

This protocol yields a clear solution of ≥ 10 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (100.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 6.25 mg/mL (18.04 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 6.25 mg/mL (18.04 mM); Clear solution

This protocol yields a clear solution of ≥ 6.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (62.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 1.67 mg/mL (4.82 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Chen X, et al. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One. 2013 May 21;8(5):e63697. [Content Brief]

[2]. You P, et al. Brevilin A induces apoptosis and autophagy of colon adenocarcinoma cell CT26 via mitochondrial pathway and PI3K/AKT/mTOR inactivation. Biomed Pharmacother. 2018 Feb;98:619-625. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8867 mL	14.4333 mL	28.8667 mL	72.1667 mL
	5 mM	0.5773 mL	2.8867 mL	5.7733 mL	14.4333 mL
	10 mM	0.2887 mL	1.4433 mL	2.8867 mL	7.2167 mL
	15 mM	0.1924 mL	0.9622 mL	1.9244 mL	4.8111 mL
	20 mM	0.1443 mL	0.7217 mL	1.4433 mL	3.6083 mL
	25 mM	0.1155 mL	0.5773 mL	1.1547 mL	2.8867 mL
	30 mM	0.0962 mL	0.4811 mL	0.9622 mL	2.4056 mL
	40 mM	0.0722 mL	0.3608 mL	0.7217 mL	1.8042 mL
	50 mM	0.0577 mL	0.2887 mL	0.5773 mL	1.4433 mL
	60 mM	0.0481 mL	0.2406 mL	0.4811 mL	1.2028 mL
	80 mM	0.0361 mL	0.1804 mL	0.3608 mL	0.9021 mL
	100 mM	0.0289 mL	0.1443 mL	0.2887 mL	0.7217 mL

Keywords

Brevilin A

5 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

Brevilin A

Apoptosis Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Terpenoids Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Autoimmune Disease Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Posttranslational Modification Library

Natural Product Diversity Scaffold Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Brevilin A

Ver todos los productos específicos de isoformas JAK

Ver todos los productos específicos de isoformas STAT

Actividad biológica

Chemical Information

Publications (5)

Solvente y solubilidad

Pureza y Documentación

Referencias

Help & FAQs

Complete Stock Solution Preparation Table

Brevilin A Related Classifications

HY-N2959 Related Classifications